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Since the advent of insulin, the improvements in diabetes detection and the therapies to treat hyperglycemia have reduced the
mortality of acute metabolic emergencies, such that today chronic complications are the major cause of morbidity and mortality
among diabetic patients. More than half of the mortality that is seen in the diabetic population can be ascribed to cardiovascular
disease (CVD), which includes not only myocardial infarction due to premature atherosclerosis but also diabetic cardiomyopathy.
The importance of renin-angiotensin-aldosterone system (RAAS) antagonism in the prevention of diabetic CVD has demonstrated
the key role that the RAAS plays in diabetic CVD onset and development. Today, ACE inhibitors and angiotensin II receptor
blockers represent the first line therapy for primary and secondary CVD prevention in patients with diabetes. Recent research has
uncovered new dimensions of the RAAS and, therefore, new potential therapeutic targets against diabetic CVD. Here we describe
the timeline of paradigm shifts in RAAS understanding, how diabetesmodifies the RAAS, andwhat new parts of the RAAS pathway
could be targeted in order to achieve RAAS modulation against diabetic CVD.
1. Introduction
Cardiovascular diseases (CVD) are the main cause of
diabetes-related morbidity and mortality [1, 2]. They include
myocardial infarction, which is due to premature atheroscle-
rosis, and diabetic cardiomyopathy, both leading to heart
failure. Patients with diabetes have a higher prevalence of
cardiovascular morbidity and mortality as compared to the
general population [3], such that diabetes is considered not
only as an independent cardiovascular risk factor but also as
a cardiovascular event equivalent, meaning that patients with
diabetes have a risk of cardiovascular complications equal
to that of patients with a prior myocardial infarction [4].
This excess cardiovascular risk in comparison to the general
population is explained only partly by conventional cardio-
vascular risk factors, such as hyperglycemia, dyslipidemia,
hypertension, and cigarette smoking.
One of the links between diabetes and such a high
prevalence of CVD is renin-angiotensin-aldosterone system
(RAAS) activation. It has been shown that the RAAS plays
a major role in the development of diabetic cardiovascular
complications [5], as it promotes atherosclerosis [6, 7],
cardiomyocyte loss, and extensive myocardial fibrosis [8, 9].
Consistent with this view, ACE inhibitors and angiotensin II
receptor blockers represent the first line therapy for primary
and secondaryCVDprevention in patients with diabetes [10].
Recent research has uncovered new dimensions of the RAAS
and, therefore, new potential therapeutic targets against dia-
betic CVD. Here we describe the timeline of paradigm shifts
in RAAS understanding, how diabetes modifies the RAAS,
and what new parts of the RAAS pathway could be targeted
in order to achieve RAAS modulation against diabetic CVD.
2. Paradigm Shifts in the
Renin-Angiotensin-Aldosterone
System Understanding
2.1. The Renin-Angiotensin-Aldosterone System Has He-
modynamic and Nonhemodynamic Actions. The renin-
angiotensin-aldosterone system (RAAS) consists of a group
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of enzymes and peptides whose main function is to control
blood pressure by regulating vasoconstriction, sodium reab-
sorption, and body fluid homeostasis.Themodern viewof the
RAAS began with the concept that this was a life-saving sys-
tem, which raised blood pressure by approximately 30mmHg
in case of an acute hemorrhage [11]. Classically, the process
whereby the RAAS raises blood pressure usually starts within
the kidney, where a blood pressure fall stimulates renin
release into the bloodstream [12, 13]. Then, circulating renin
cleaves hepatic angiotensinogen and generates angiotensin
(Ang) I, which is converted to Ang II by pulmonary
angiotensin-converting enzyme (ACE), as represented in Fig-
ure 1 [14–16]. Soon after its generation, Ang II causes smooth
muscle cell vasoconstriction, stimulates the sympathetic ner-
vous system, and promotes renal retention of salt and water
by binding to its specific receptors [17, 18]. Moreover, in the
adrenal glands, Ang II stimulates the release of aldosterone,
which enhances tubular sodium reabsorption in the kidney
and increases the effective circulating plasma volume [19].
Ang II has two main receptors: Ang II type 1 receptor
(AT1R) and Ang II type 2 receptor (AT2R), as represented
in Figure 2. Studies in mice lacking AT1R showed that the
hemodynamic actions of Ang II depended on AT1R [20–
22]. On the other hand, AT2R, which was found highly
expressed in differentiated mesenchymes during fetal life
and decreased rapidly after birth, seemed to regulate fetal
development [18, 23]. Nevertheless, AT2R is still detectable
in adulthood in different organs, such as the heart, kidney,
adrenal glands, brain, ovaries and uterus, and the vessels
[24], where its main function is to counterbalance AT1R. For
instance, AT2R-knockout mice exhibit high blood pressure
levels and increased vascular sensitivity to Ang II [25, 26],
suggesting that AT2R antagonizes AngII-AT1R peripheral
effects. Such an action could be achieved not only by
vasodilator effects that are independent of AT1R [27, 28] but
also by AT1R downregulation [29] and/or direct inhibition of
AT1R signaling [30, 31], as represented in Figure 2.
Although the RAAS was a life-saving system, the first
aspect that became clear was that if the Ang II cascade
was activated inappropriately, it could lead to hypertension
and CVD [32]. Therefore, ACE inhibitors and Ang II type 1
receptor blockers (ARB) were designed as antihypertensive
therapies [33, 34]. A paradigm shift in RAAS understanding
occurred when the CONSENSUS and the SOLVD trials
showed that theACE inhibitor Enalapril reduced overallmor-
tality by 27% and 16% in patients with heart failure [35, 36].
Enalapril’s benefit suggested that the RAAS had significant
nonhemodynamic actions that were associated with cardio-
vascular pathology. These trials led to mechanistic studies
demonstrating that Ang II promoted ventricular hypertrophy
[37–39], myocardial infarction [40], and atherosclerosis [41–
43], independent of blood pressure values. In particular, by
binding to AT1R, Ang II was able to induce reactive oxygen
species generation, tissue inflammation and fibrosis, and
the regulation of cell growth and differentiation as well as
apoptosis and survival as summarized in Table 1 [41–63].
2.2. Circulating and Tissue Renin-Angiotensin-Aldosterone
System. The observation that many tissues were capable
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Figure 1: The activation of systemic renin-angiotensin-aldosterone
system cascade for blood pressure control. The activation of the
circulating RAAS cascade that follows a blood pressure fall begins
with renin secretion by the kidney. Once it has been released
into the bloodstream, renin cleaves angiotensinogen to form Ang
I, which is then converted to Ang II by pulmonary ACE. Ang
II stimulates vasoconstriction, renal retention of salt and water,
aldosterone secretion, and sympathetic activity, whereby it increases
blood pressure. ACE is for angiotensin-converting enzyme; Ang is
for angiotensin; RAAS is for renin-angiotensin-aldosterone system.
of synthesizing the RAAS key components led to another
paradigm shift in the timeline of RAAS understanding: the
RAAS was not anymore only a circulating hormonal system
but also a tissue system widespread in cardiovascular organs
[64–68]. ACE and Ang II receptors were identified in all
the relevant target tissues including the heart, kidney, blood
vessels, and adrenal glands [69–71], where they have not
only endocrine but also paracrine and autocrine effects [72].
Interestingly, circulating and local systems can sometimes
behave in opposite ways, like in cases of high salt intake,
which generally downregulates circulating and upregulates
local RAAS [73].
Renin, angiotensinogen, ACE, and Ang II receptors were
all present in the heart [67], where they were found upreg-
ulated in models of cardiac injury, such as volume overload
[74], myocardial infarction [75], and heart failure [76–78].
For example, one of the first experimental observations was
that ACE increased in heart failure, its cardiac induction was
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Figure 2: Angiotensin II receptors. Angiotensin II has two major receptor isoforms: Ang II type 1 receptor (AT1R) and Ang II type 2
receptor (AT2R). AT1R stimulation mediates the classical actions of Ang II, including hemodynamic and nonhemodynamic effects, leading
to hypertension, cardiac remodeling, and atherosclerosis. On the other hand, AT2R stimulation usually causes opposing effects to AT1R.
Moreover, it can antagonize AT1R by downregulating it, inhibiting its signaling, or binding to it. Ang is for angiotensin; AT1R is for Ang II
type 1 receptor; AT2R is for Ang II type 2 receptor; NO is nitric oxide.
tissue specific, and it correlated with the size of myocardial
infarction [76]. Interestingly, ACE was expressed not only
in the cardiomyocytes adjacent to the infarct size, but also
in fibroblasts, macrophages, and endothelial cells. Further
studies demonstrated that the increase in cardiac ACE was
functionally significant, as it was associated with an increased
intracardiac conversion of Ang I to Ang II, which could
potentially impair ventricular function and induce ventric-
ular arrhythmias [79], eventually promoting heart failure.
Almost a decade after the CONSENSUS and the SOLVD
studies, the HOPE [5] trial extended to high-risk patients,
such as those with diabetes, the concept that RAAS blockade
protected against cardiovascular morbidity and mortality.
In that trial, Ramipril significantly reduced the rates of
death, myocardial infarction, and stroke in patients with
vascular disease or diabetes. Likewise, the LIFE trial showed
that Losartan was more effective than Atenolol in reducing
cardiovascular morbidity and mortality in patients with
hypertension, diabetes, and ventricular hypertrophy [80].
Also the EUROPA [81] and ADVANCE [82] trials provided
evidence that an ACE inhibitor treatment improved survival
and reduced the risk of major cardiovascular events in
patients with diabetes. Consistent with these results, exper-
imental studies demonstrated that Ang II blockade signif-
icantly reduced cardiac damage [8, 9] and atherosclerotic
plaque accumulation [6, 7] in the context of diabetes. More
recently, the ONTARGET trial has evaluated whether the
combination of an ACE inhibitor with an ARB was better
than the full dose of either drug. In the end, there was no
superiority of the ACE inhibitor versus the ARB in terms
of cardiovascular events. Moreover, dual blockade did not
confer greater cardiovascular protection and it actually put
risk of more adverse events [83].
At the same time the RALES and EPHESUS trials showed
that aldosterone antagonism on top of Ang II blockade
provided a major additive benefit as it reduced significantly
overall mortality and the rate of death from cardiovascular
causes among patients with severe heart failure [84] or after
acute myocardial infarction [85].These results suggested that
Ang II blockade could not totally suppress the production
of aldosterone and that other factors in addition to Ang II
were important in the production of this hormone.Moreover,
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Table 1: Cellular and tissue effects of Ang II, Ang 1–7, aldosterone, and (pro)renin in normal conditions.
Ang II
(via AT1R∗)
Ang 1–7
(via Mas1R∗)
Aldosterone
(via MR∗)
(Pro)renin
(via (P)RR∗)
Cardiomyocytes Hypertrophy [44] Hypertrophy inhibition[112, 113]
Hypertrophy [86]
Apoptosis [87]
Oxidative stress [87]
Hypertrophy [136, 137]
Hyperplasia [138]
Cell elongation [139]
Cardiac fibroblasts
Proliferation [44]
Extracellular matrix
production [45–48]
Antiproliferative effects
[114, 115]
Inhibition of collagen
production [115]
Proliferation and migration
[88]
Extracellular matrix
production (collagen/elastin)
[48, 89, 90]
Endothelial cells Oxidative stress [49]Inflammation [50, 51]
Nitric oxide production [116]
Anti-inflammatory effects
[117]
Oxidative stress [91]
Inflammation [92]
Hyperplasia [140]
Survival [140]
Smooth muscle cells
Oxidative stress [52]
Hypertrophy [53, 54]
Proliferation [55]
Migration [56, 57]
Extracellular matrix
production [58]
Antiproliferative effects
[118, 119]
Proliferation [93]
Migration [94]
Extracellular matrix
production [95, 96]
Hyperplasia [141, 142]
Survival [142]
Oxidative stress [142]
Macrophages Inflammation [51, 59] Anti-inflammatory effects[120]
Inflammation [97]
Oxidative stress [98] Inflammation [143]
Heart
Hypertrophy [60]
Fibrosis [61]
Apoptosis [62, 63]
Antiarrhythmic effects [121]
Antifibrotic effects [122]
Antiremodeling effects
[123–126]
Hypertrophy [99]
Fibrosis [100]
Proarrhythmogenic [101]
Inflammation [102]
Cardiac function
deterioration [144]
Fibrosis [144]
Angiogenesis [144]
Vessels
Impaired vascular
relaxation to Ach [52]
Atherosclerosis [41–43]
Vasodilation [127, 128]
Antiatherosclerotic effects
[128]
Impaired vascular relaxation
to Ach [91]
Atherosclerosis [103]
Angiogenesis [140, 145]
∗Cellular and tissue effects are predominantly mediated by the indicated receptors.
Ang is for angiotensin; AT1R is for Ang II type 1 receptor;Mas1R is forMas1 receptor;MR is formineralocorticoid receptor; and (P)RR is for (pro)renin receptor.
they reinforced the notion that aldosterone promoted organ
damage by a series of cellular and tissue effects, elicited by
binding predominantly to the mineralocorticoid receptors,
which are reported in Table 1 [86–103]. More recently,
Eplerenone benefits have been extended to diabetic patients,
where this treatment reduced adverse CV events in diabetic
patients with heart failure following myocardial infarction
[104]. A randomized study evaluating the effects of two
aldosterone antagonists, Finerenone versus Eplerenone, in
diabetic patients with heart failure is still ongoing [105].
2.3. ACE2 and (Pro)Renin Discovery. Nevertheless, ACE2
discovery represents perhaps the last fundamental paradigm
shift in RAAS understanding [106, 107]. ACE2 is a car-
boxypeptidase whose main function is to degrade Ang II
to generate Ang 1–7, as represented in Figure 3. Although
ACE2 can also degrade Ang I to generate Ang 1–9, its catalytic
efficiency is 400-fold higher with Ang II, and therefore its
main effect is the degradation of Ang II to Ang 1–7 [108,
109]. Ang 1–7 is a biologically active peptide, which exerts
opposite peripheral actions to those of Ang II [110] by binding
predominantly to the Mas1 receptor (Mas1R) [111]. Cellular
and tissue effects of Ang 1–7/Mas1R are summarized in Table 1
[112–128]. Moreover, Ang 1–7, like all Ang II “breakdown”
products, has the potential to act as an endogenous ligand of
AT2R [129], further promoting organ protection (Figure 3).
The identification of ACE2 provided evidence that the
RAAS had two pathways with opposite effects: the classic
ACE/Ang II/AT1R and the new ACE2/Ang 1–7/Mas1R (and
AT2R) pathway. Accordingly, the current scientific opinion
is that what is critical in CVD development is an imbalance
in ACE-Ang II and ACE2-Ang 1–7 [130]. Consistent with this
view, ACE2 is regarded as the central regulator of the RAAS
[131], as its changes can affect not only Ang II detrimental
actions but also Ang 1–7 protective effects. For instance, a
decrease inACE2 results in activation of theAng II/AT1R axis
with a parallel reduction of Ang 1–7 [51, 132]. Nevertheless,
ACE2 protective effects can be attributed not only to the
degradation of Ang II and the generation of Ang 1–7 or to
the degradation of Ang I and the generation of Ang 1–9 [106],
as represented in Figure 3, but also to the local increase of
ANP. Recently, we have shown that ACE2 regulates ANP
production through Ang 1–7 [132].
Having said that, the final entry in the RAAS is the
(pro)renin receptor [(P)RR], which is a specific receptor
for both renin and its inactive precursor prorenin [133],
collectively called (pro)renin (Figure 3). When (pro)renin
binds to (P)RR it can degrade angiotensinogen to Ang I,
but it can also trigger intracellular signaling pathways, which
are independent of Ang II generation [133]. Interestingly, the
ability of prorenin to activate the RAAS depends on the fact
that its binding induces a conformational change that exposes
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Figure 3: Tissue renin-angiotensin-aldosterone system. The activation of the RAAS cascade begins with renin secretion. Renin is secreted
as a precursor protein, prorenin. Renin and prorenin can bind to their specific receptor called (P)RR and activate intracellular pathways
independent of RAAS. Otherwise, renin cleaves angiotensinogen to form Ang I, which is then converted to Ang II by ACE. Ang II binds
to its specific receptors: AT1R and AT2R. AT1R promotes blood pressure increase, cardiac remodeling, and atherosclerosis development. In
addition, through AT1R, Ang II stimulates aldosterone secretion. On the other hand, AT2R seems to antagonize these effects. Moreover, Ang
I and Ang II can be cleaved by ACE2 to form Ang 1–9 and Ang 1–7, which have opposite effects to those of Ang II, such as vasodilation, anti-
inflammatory, antifibrotic, and antiremodeling effects, which are mediated by Mas1R and partly by AT2R. In addition, Ang 1–7 stimulates
local ANP secretion. ACE is for angiotensin-converting enzyme; ACE2 is for angiotensin-converting enzyme 2; Ang is for angiotensin; AT1R
is for Ang II type 1 receptor; AT2R is for Ang II type 2 receptor; ANP is for atrial natriuretic peptide; (P)RR is for (pro)renin receptor.
prorenin active site, which becomes catalytically active and
generates Ang I. The biology of (P)RR is very complex and
only partially understood [134]. The association between
(P)RR gene polymorphism and ambulatory BP in Japanese
men [135] has suggested that (P)RR was related to cardio-
vascular disease leading to experimental studies supporting
this hypothesis. The cellular and tissue effects of (pro)renin
are reported in Table 1 [136–145]. Nevertheless, transgenic
animals overexpressing (pro)renin developed hypertension
that was sensitive to ACE inhibition, indicating that this
effect was due to Ang II generation, which led to arguing
against an independent role of (P)RR in CVD [146, 147].
On the other hand, Batenburg and Danser have suggested
that (pro)renin overexpression led to a 400-fold increase of
plasma (pro)renin levels, which is far from the 1000-fold–
100.000-fold increase that is required to observe (pro)renin
effects in vitro [148]. Certainly, (P)RR has essential functions
that are independent of the RAAS and are related to the
vacuolar H+-proton adenosine triphosphatase (V-ATPase)
[149]. In particular, (P)RR is a cofactor of the V-ATPase
[150] and is required for central nervous system development
[151, 152]. (P)RR is also an essential partner in Wnt receptor
complex signaling [153], which regulates normal pattering
of the embryo, and in adults, cell proliferation, migration,
polarity, and tissue repair. These findings explain not only
why (P)RR deletion yielded embryos that died before the end
of embryogenesis [153, 154] but also why mice with specific
ATP6ap2/(P)RR knockout in cardiomyocytes died of severe
heart failure within 3 weeks of age [155].
3. Diabetes, the Activation and Imbalance of
the Renin-Angiotensin-Aldosterone System,
and Cardiovascular Disease
3.1. The Renin-Angiotensin-Aldosterone System Activation
Links Diabetes to CVD. The current picture of the RAAS is
that of an extremely complex pathway whose overstimulation
triggers a chain of events contributing to cardiovascular
disease. The RAAS is found not only in the circulation,
where it has hemodynamic effects, but also at a tissue level,
where it has nonhemodynamic effects. It is activated in
the hypertrophied, ischemic, and failed heart, and activa-
tion of the ACE/AngII/AT1R axis leads to both accelerated
atherosclerosis and direct cardiac injury, as shownby infusing
Ang II or by the studies where RAAS blockade was able to
attenuate or prevent cardiac damage [78].
Patients with diabetes have a higher prevalence of cardio-
vascular morbidity and mortality as compared to the general
6 Journal of Diabetes Research
population [3]. On one hand, diabetes is associated with
accelerated atherosclerosis affecting the coronaries, which
increases the risk for myocardial infarction and heart failure.
On the other hand, it can cause diabetic cardiomyopathy,
which corresponds to a cardiac dysfunction independent of
coronary artery disease, hypertension, and valvular compli-
cations [156].
Upregulation of the RAAS is evident in diabetes. Miller
and colleagues demonstrated that during the early stages
of diabetes there was an increase in plasma renin activity,
mean arterial pressure, and renal vascular resistance [157].
Moreover, the fact that Losartan lowered blood pressure
more in hyperglycemic than in euglycemic conditions [158],
and that Captopril and Eprosartan caused a greater renal
vasodilator response during hyperglycemia [159], suggested
that glucose levels were associated with an activation of
the RAAS, which made diabetic patients more sensitive to
RAAS antagonism. Consistent with this view, direct renin
inhibition with Aliskiren led to significant improvement of
left ventricular hypertrophy [160] and end-systolic volume
[161] only in groups of patients with diabetes.
The importance of RAAS antagonism in the preven-
tion/reduction of cardiovascular complications has clearly
demonstrated that diabetes-induced RAAS activation con-
tributes substantially to diabetic CVD [5, 80–82]. Activation
of AngII/AT1R pathway in the setting of diabetes can in fact
promote cell growth and proliferation, apoptosis [162], oxida-
tive stress generation [9], inflammation [6], and fibrosis [9],
which are all leading to cardiac remodeling and atherosclero-
sis, that can be reversed/reduced by RAAS blockade [7–9].
3.2. Diabetes-Induced Activation of the AngII/AT1R Pathway
and Imbalance of the Renin-Angiotensin-Aldosterone System.
There are several mechanisms whereby diabetes can promote
tissue Ang II/AT1R actions. Firstly, hyperglycemia directly
stimulates local Ang II production in cardiomyocytes [163],
cardiac fibroblasts [164], and endothelial cells [165] as well as
in murine and human diabetic heart tissues [164, 166]. For
example, Fiordaliso and colleagues demonstrated that glu-
cose increased Ang II in cardiac myocytes, which made them
more susceptible to undergo apoptosis [167], consistent with
the view that the RAAS promotes the development of diabetic
cardiomyopathy [162, 166]. Studies on cardiac myocytes sug-
gest that the mechanism whereby hyperglycemia increases
local Ang II in the heart is the generation of intracellular
Ang II by intracellular chymase and/or internalized prorenin.
Then, intracellular Ang II could directly produce oxidative
stress and cellular apoptosis and/or enhance RAAS com-
ponents expression through a positive feedback mechanism
[168].
The second mechanism underlying AngII/AT1R activa-
tion in diabetes is that high glucose concentrations can
enhance the tissue response to Ang II and vice versa.
While Ang II can increase the activation of glucose-induced
transcription factors in vascular smooth muscle cells [169],
hyperglycemia can increase the contractile aortic response to
Ang II [170]. This additive effect could be ascribed to the fact
that diabetes induces AT1R expression in the heart [171, 172]
and the vasculature [172]. Interestingly, several works have
demonstrated that hyperglycemia can also stimulate aldos-
terone secretion by increasing local Ang II. Xue and Siragy
observed an upregulation of renal aldosterone synthase in
diabetic rats, which was significantly reduced by AT1R block-
ade [173]. Similar findings were reported in podocytes [174]
and in cardiomyocytes [175]. Locally, aldosterone triggers a
vicious cycle that promotes AngII/AT1R effects as it mediates
part of Ang II effects [176], increases tissue ACE and AT1R
[177], and reduces tissue ACE2 [178, 179]. Moreover, together
with Ang II, aldosterone promotes oxidative stress, fibrosis,
and apoptosis. Therefore, many studies are now supporting
at least a synergistic role for aldosterone in the pathogenesis
of diabetic cardiovascular complications [180].
The third way whereby diabetes promotes Ang II tissue
actions is through the several metabolic abnormalities asso-
ciated with hyperglycemia.These include advanced glycation
end products, which form after prolonged hyperglycemia and
oxidative stress, dyslipidemia, and low-grade inflammation.
All of them can in fact stimulate the AngII/AT1R pathway
by upregulating AT1R expression [181–184]. An interesting
aspect that should be considered is that, in the heart, the
conversion of Ang I to Ang II relies not only on ACE activity
but also on other enzymes such as tissue chymase [185, 186],
which are found primarily in mast cells. Given this localiza-
tion, chymase might link inflammation to RAAS activation
and CVD. Unfortunately, inhibition of this chymase is yet to
be realized [187].
Another intriguing mechanism whereby diabetes
enhances AngII/AT1R actions is ACE2 downregulation,
which does not only promote Ang II actions but also reduce
local Ang 1–7 leading to an imbalance of the RAAS. This
concept is supported by the works of Tikellis and colleagues,
who showed that the induction of diabetes was associated
with a significant reduction of ACE2 expression and ACE2
activity in the heart and the vasculature [172] together with
a significant increase in circulating Ang II and a significant
reduction of Ang 1–7 levels [172]. Similar changes were
reported in the kidney of diabetic mice [132, 188]. It has
been argued that ACE2 may be more important than ACE in
regulating cardiac levels of Ang II and Ang 1–7 and therefore
more important for balancing RAAS activation [189]. This
concept relies on the experimental evidence that while ACE2
deficiency results in increased cardiac levels of Ang II [51]
and reduced levels of Ang 1–7 [132], ACE deficiency does
not modify cardiac Ang II, which could be generated by
non-ACE pathways [190], including chymases.
Therefore, ACE2 replenishing strategies could be an
important therapeutic tool against diabetic CVD. Another
promising therapeutic strategy against diabetic CVD seems
to be AT2R stimulation. The rationale behind it is that
diabetes seems to upregulate AT2R expression [24]. AT2R
expression was found increased in the hearts of diabetic rats
[171, 191], as well as in their kidneys [192]. Similar results were
obtained in kidney biopsies of patients with type 2 diabetes
[193]; this is in line with the report that glucose inducedAT2R
renal expression both in vivo [194, 195] and in vitro through
the expression of the transcriptor factor IRF-1 [195].
Lastly, diabetic patients have higher prorenin levels
than normal subjects, and their prorenin levels are 10-fold
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higher than their renin levels [196]. Given that the bind-
ing of prorenin to (P)RR can generate Ang I and also
stimulate (P)RR intracellular signaling, it has been argued
that plasma prorenin could contribute more substantially
than renin to the pathogenesis of end-organ damage [196].
This is supported by the finding that diabetic patients with
high prorenin levels had a higher risk of microvascular
complications [197], whose development could be predicted
by the same prorenin levels [198]. Consistent with these
circulating changes, Connelly and colleagues demonstrated
that, also at a tissue level, diabetic cardiomyopathy was
associated with a 3-fold increase in both (P)RR gene and
protein expression, whichwere reduced by the renin inhibitor
Aliskiren. Although the increased expression of (P)RR in the
diabetic heart was interpreted as a beneficial response to limit
intracellular acidosis, due to its sequence identity with the
V-ATPase, it was argued that (P)RR abundance could still
modulate the activity of the local RAAS and expose cardiac
myocytes to Ang II increased concentrations [199].
4. New Potential Therapies against Diabetic
Cardiovascular Complications
4.1. New Agents for Classic Targets
4.1.1. Angiotensin Receptor-Neprilysin Inhibition. ACE inhi-
bition, AT1R antagonism, and MR blockade are some of
the most classic therapeutic strategies against CVD. Another
classic therapeutic strategy against heart failure is to increase
natriuretic peptide levels, as they are natriuretic, diuretic,
vasodilating, and able to inhibit pathologic growth in heart
failure [200]. However, although the idea to boost their
activity in patients with heart failure seemed theoretically
infallible, the approaches used for years have produced
only partial if not disappointing effects. These approaches
included short-term intravenous infusions of natriuretic
peptides or inhibition of neprilysin, which is the enzyme
that degrades natriuretic peptides, together with bradykinin,
adrenomedullin, and possibly other substrates such as Ang II.
So, the most likely explanation underlying the disappointing
effect of the oral inhibitor of neprilysin was that neprilysin
degraded also Ang II, and therefore inhibiting neprilysin
would increase not only natriuretic peptides but also Ang
II actions. Eventually, the combination of an ACE and a
neprilysin inhibitor solved this problem and turned out to
be superior to either approach in terms of cardiovascu-
lar benefits [201, 202]. Unfortunately, in clinical trials this
combination was associated with angioedema [203, 204]. In
order to overcome this issue, angiotensin receptor-neprilysin
inhibitors (ARNis) have been developed, such as LCZ696,
which is an association of the ARB Valsartan with the
neprilysin inhibitor Sacubitril (Figure 4). In a recent trial this
association was found superior to Enalapril in reducing the
risk of death and hospitalization in patients with heart failure
[205], including those with diabetes [206]. This is consistent
with the observation that the administration of LCZ696 in an
experimental model of diabetes significantly reduced cardiac
hypertrophy and fibrosis and improved ejection fraction after
myocardial reperfusion injury [207].
4.1.2. Aldosterone Synthase Inhibition. Another classic target
against CVD is aldosterone, due to the growing appreci-
ation of its contribution to CVD development and pro-
gression. The drugs that are available for blocking aldos-
terone actions are Spironolactone and Eplerenone, which are
both mineralocorticoid-receptor antagonists. Nevertheless,
Spironolactone and Eplerenone have still limited clinical use,
due to the poor selectivity of Spironolactone, the low potency
of Eplerenone, and the fact that only MR-dependent effects
of aldosterone can be inhibited. An alternative approach to
antagonize aldosterone is inhibiting its formation. For this
reason, several aldosterone synthase (CYP11B2) inhibitors
have been developed. The compounds targeting CYP11B2
that have been studied so far are FAD286, which has been
used mostly in experimental settings, and LCI699, which has
been developed for human use in 2010 [208]. A few works
have demonstrated that FAD286 reducedmortality, improved
cardiac remodeling [209, 210], and reduced atherosclerosis
[211]. Nevertheless, both drugs have exhibited clear side
effects due to the inhibition of CYP11B1, which synthesizes
glucocorticoids. Moreover, another concern prior to their
use is that aldosterone synthase inhibitors could allow the
activation of unprotected MR by glucocorticoids, and this
needs further research.
4.1.3. Renin Inhibition. Renin inhibition represents another
very attractive therapeutic strategy to reduce Ang II levels.
This can be achievedwith the renin inhibitorAliskiren, which
attenuates Ang II generation and reduces blood pressure
comparably to ACE inhibitors and ARB [212]. However,
similarl to what was reported in the ONTARGET trial, the
ALTITUDE study has demonstrated that the simultaneous
administration of Aliskiren with an ACE inhibitor or an ARB
should be avoided [213]. A critical concern on the use of
Aliskiren is that it is associated with high renin levels that
might bind to (P)RR [214, 215]. Therefore, specific blockade
of (P)RR could provide more benefits as compared to renin
inhibition alone, as it could not only reduce (pro)renin
enzymatic activity but also prevent some AngII-independent
effects of (pro)renin. So far, a (P)RR antagonist, called HRP
(“handle region” peptide), has been designed. In particular,
this molecule mimics the “handle region” of prorenin, which
allows its binding to (P)RR and its subsequent nonproteolytic
activation. Studies in animalmodels of diabetes showpromis-
ing results as reviewed in [148], possibly because HRP exerts
its effects only in diseases associated with high prorenin and
low renin levels, such as diabetes.
4.2. New Agents for New Targets
4.2.1. ACE2 Replenishing Strategies. A promising therapeutic
strategy in cardiovascular medicine is represented by RAAS
modulation. As compared to RAAS antagonism, RAAS
modulation combines ACE/AngII/AT1R blockade with the
stimulation of ACE2/Ang 1-7/Mas1R and AT2R. The latter
can be achieved by a series of new therapies that includes
ACE2 replenishing strategies, Ang 1–7 administration, and
AT2R agonists. However, also ACE inhibitors and AT1R
blockers should be considered RAAS modulating agents,
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Figure 4: Mechanisms of action of angiotensin receptor/neprilysin inhibitors. ARB antagonize Ang II binding to AT1R, which causes
hypertension and multiorgan injury. NEPi inhibit the activity of NEP, which is an enzyme degrading natriuretic peptide, bradykinin, and
other peptides. The result is a reduction of Ang II harmful effects and an increase of the benefits of natriuretic peptides and bradykinin. ACE
is for angiotensin-converting enzyme; ADM is for adrenomedullin; Ang is for angiotensin; ANP is for atrial natriuretic peptide; ARB is for
angiotensin II receptor blockers; AT1R is for Ang II type 1 receptor; BNP is for brain natriuretic peptide; NEPi is for neprilysin inhibitors.
as they can increase ACE2 expression and Ang 1–7 levels
severalfold, suggesting that part of their beneficial effects is
due to ACE2/Ang 1–7 effects [216, 217].
Having said that, Crakower and colleagues showed that
ACE2 is an essential regulator of cardiac function, by demon-
strating that ACE2 deficiency was associated with reduced
systolic function [218]. Similar findings have been reported
in animal models of type 1 and type 2 diabetes [219, 220]. In
addition to that, we have demonstrated that ACE2 deficiency
was associatedwith accelerated atherosclerosis [51]. It has also
to be noted that ACE2 deficiency might in fact influence not
only the risk of developing CVD but also the response to
the treatment, particularly in the setting of diabetes where
ACE2 expression is constitutively low [188]. These findings
emphasize the potential utility of ACE2 repletion as a strategy
to reduce CVD. Current therapeutic tools that modulate
ACE2 levels or activity, which are still under investigation,
include adenoviral ACE2 gene transfer, recombinant human
ACE2 (rhACE2), ACE2 activators, oral ACE2, and Ang 1–7
bioencapsulated in plant cells. So far, bothACE2 gene transfer
and the administration of an ACE2 activator have ame-
liorated diabetic cardiomyopathy [221, 222]. Moreover, the
reports that rhACE2 administered intravenously to healthy
human subjects was well tolerated [223] and that it resulted
in sustained reduction in plasma Ang II levels and elevation
in Ang 1–7 levels [131] are encouraging, as they are shortening
the gap between bench and bedside with respect to the
possibility of using rhACE2 in clinical practice.
4.2.2. Ang 1–7 Administration. Based on the protective car-
diovascular effects of Ang 1–7, several experimental studies
have tested the hypothesis that Ang 1–7 infusion could
ameliorate diabetic cardiomyopathy. In all these works, Ang
1–7 improved all the structural hallmarks of diabetic car-
diomyopathy, which is characterized by left ventricle hyper-
trophy and left and right ventricle fibrosis and dysfunction
[224–226]. In db/db mice with early [227] and advanced
disease [228], Ang 1–7 reversed diabetes-induced changes.
In particular, in the early disease model [227], Ang 1–7
increased cardiac output and cardiac index and decreased
cardiomyocyte hypertrophy, heart fibrosis, and inflamma-
tion. Vascularization was also improved, which correlated
with increased numbers of bone marrow residing in and
circulating endothelial and mesenchymal stem cells [227].
Here, Mas1R seemed to be the main receptor mediating
Ang 1–7 effects, which explains why AVE0991, which is a
Mas1R agonist, had cardioprotective effects in diabetic rats
[229]. In addition, in the advanced disease model, Ang 1–7
ameliorated diastolic function and decreased not only cardiac
hypertrophy and fibrosis but also triacylglycerol accumula-
tion [228]. Moreover, consistent with the report that Ang 1–
7 preserved cardiac function, coronary perfusion, and aortic
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endothelial function in a rat model of heart failure [230], Ang
1–7 improved cardiac recovery from ischemia/reperfusion
and restored the normal reactivity to constrictor and dilator
stimuli in the vasculature [231]. Recently, we have shown
that Ang 1–7 administration significantly reduced ex vivo
leukocyte recruitment in an animal model of diabetes. This
was associated with a reduction of glucose-induced molecule
adhesion expression and leukocyte adhesion to endothelial
cells in vitro [232]. These effects were completely blocked by
the Mas1R antagonist, suggesting that Mas1R was the main
receptor mediating Ang 1–7 effects on endothelial cells.
4.2.3. AT2R Agonists. AT2R activation has been currently
achieved by compound 21 (C21), which is a nonapeptide that
acts as a highly selective AT2R agonist and stimulates AT2
receptors. Several studies have shown its efficacy in reducing
tissue fibrosis in the cardiovascular system. However, those
that have been carried out in diabetic conditions have
explored its actions mostly against renal fibrosis. In this
setting, C21 was able to significantly reduce renal fibrosis in
experimental models of both type 1 [233] and type 2 diabetes
[234]. In one of these studies, C21 was able to significantly
reduce also the expression of several inflammatorymediators
[233]. This finding is consistent with the vascular effects of
this drug, which prevented endothelial inflammation and
reduced leukocyte adhesion both in vivo and in vitro [235].
In addition, recently, C21 was found to be able to reduce
diabetes-associated atherosclerosis [236].
5. Conclusions
The RAAS has been studied for more than a century. Never-
theless, the current picture of theRAAS is that of an extremely
complex pathway, which has not been fully characterized yet
and might hold in store new aspects that have still to be
discovered. Certainly, what we do know is that blocking Ang
II reduces cardiovascular complications. This is particularly
true in diabetic conditions, where Ang II/AT1R pathway is
activated, while the Ang 1–7/Mas1R is not.Therefore, the aim
of new therapies is not only to block Ang II harmful effects
but also to augment the activity and actions of potentially
beneficial pathways, byACE2 replenishing strategies, Ang 1–7
administration, andAT2R agonists.Here is another paradigm
shift: treatment of diabetic cardiovascular disease should
move from RAAS inhibition to RAAS modulation.
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